Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism.

Lange, Naomi; Méan, Marie; Stalder, Odile; Limacher, Andreas; Tritschler, Tobias; Rodondi, Nicolas; Aujesky, Drahomir (2019). Anticoagulation quality and clinical outcomes in multimorbid elderly patients with acute venous thromboembolism. Thrombosis research, 177, pp. 10-16. Elsevier 10.1016/j.thromres.2019.02.017

Text Lange ThrombRes 2019.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (758kB)

BACKGROUND

Multimorbid patients with acute venous thromboembolism (VTE) are often excluded from clinical trials and little is known about their prognosis.

OBJECTIVES

To examine whether multimorbidity is associated with adverse clinical outcomes and lower anticoagulation quality in older patients with VTE.

PATIENTS/METHODS

We studied 991 patients aged ≥65 years with acute VTE in a Swiss prospective multicenter cohort study. A modified Charlson Comorbidity Index was used to measure multimorbidity, which was defined as the presence ≥2 of 17 predefined comorbid conditions. We examined the association between multimorbidity and recurrent VTE and major bleeding, adjusting for confounders and periods of anticoagulation. We assessed whether the percentage of time spent in the therapeutic international normalized ratio (INR) range varied by the number of comorbidities present.

RESULTS

Overall, 708 (71%) patients were multimorbid. Multimorbid patients had a higher 3-year cumulative incidence of recurrent VTE (16.8 vs. 10.8%; P = 0.056) and major bleeding (18.7 vs. 9.0%; P = 0.001) than non-multimorbid patients. After adjustment, multimorbid patients had a significantly higher risk of recurrent VTE (sub-hazard ratio [SHR] 1.66, 95% confidence interval [CI] 1.08-2.57) and a higher risk of major bleeding (SHR 1.55, 95% CI 0.96-2.50), although the latter failed to achieve statistical significance. With increasing numbers of comorbid conditions, patients spent less time in and more time above and below the therapeutic INR range.

CONCLUSIONS

Multimorbid patients with acute VTE have not only a lower anticoagulation quality but also more complications. Clinical trials should explicitly enroll multimorbid patients to determine the optimal anticoagulation strategy in such patients.

Interest & Impact

Downloads

2 since deposited on 06 Mar 2019
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item